RT Journal Article
T1 How to prevent and/or revert Alzheimer’s disease continuum during preclinical phases
A1 Avila Villanueva, Marina
A1 Marcos Dolado, Alberto
A1 Fernández Blázquez, Miguel Ángel
AB The development of Alzheimer’s disease (AD) follows three consecutive phases: namely preclinical, prodromal or mild cognitive impairment (MCI), and dementia. In addition, the preclinical phase can be divided into subphases related to the presence of biomarkers that appear at different points before the onset of MCI. Indeed, an early risk factor could promote the appearance of additional ones through a continuum. The presence of various risk factors may trigger specific biomarkers. In this review, we comment on how modifiable risk factors for AD may be reverted, thus correlating with a possible decrease in the specific biomarkers for the disease. Finally, we discuss the development of a suitable AD prevention strategy by targeting modifiable risk factors, thereby increasing the level of “precision medicine” in healthcare systems worldwide.
PB Sage
YR 2023
FD 2023-06
LK https://hdl.handle.net/20.500.14352/130631
UL https://hdl.handle.net/20.500.14352/130631
LA eng
NO Ávila-Villanueva M, Dolado AM, Fernández-Blázquez M. How to Prevent and/or Revert Alzheimer’s Disease Continuum During Preclinical Phases. Journal of Alzheimer’s Disease Reports. 2023;7(1):505-512. doi:10.3233/ADR220100
NO This work has been done during a Margarita Salas contract founded by Next Generation EU
DS Docta Complutense
RD 23 ene 2026